





AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:


Claims 1-137. (Cancelled)

138. (new) A compound selected from compounds of the following formulae and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



wherein:

Ar is a group of the following formula:



wherein:

R^{SO} is independently C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and is optionally substituted; and

each of R^{3N} , R^{4N} , R^{5N} , R^{6N} , and R^{7N} is independently -H, or a group independently selected from:

hydroxy (-OH);

halo;

cyano (-CN);

carboxy (-COOH);

azido;

ester;

amino, including:

amino- C_{1-7} alkyl-amino;

C_{1-7} alkyl, including:

halo- C_{1-7} alkyl;

amino- C_{1-7} alkyl;

carboxy- C_{1-7} alkyl;

hydroxy- C_{1-7} alkyl;

C_{5-20} aryl- C_{1-7} alkyl;

ether, including:

C₁₋₇alkoxy;
halo-C₁₋₇alkoxy;
amino-C₁₋₇alkoxy;
carboxy-C₁₋₇alkoxy;
hydroxy-C₁₋₇alkoxy;
C₅₋₂₀aryl-C₁₋₇alkoxy;

acyl, including:

C₁₋₇alkyl-acyl;
halo-C₁₋₇alkyl-acyl;
amino-C₁₋₇alkyl-acyl;
carboxy-C₁₋₇alkyl-acyl;
hydroxy-C₁₋₇alkyl-acyl;
C₅₋₂₀aryl-C₁₋₇alkyl-acyl;
C₅₋₂₀aryl-acyl; and
C₅₋₂₀aryl;

the group -OR⁰ is independently:

- (a) -OH; or:
- (b) an ether group; or:
- (c) an acyloxy group;

each of R², R³, R⁵, and R⁶, is independently:

(a) H; or:

(b) a monovalent monodentate substituent;

wherein each monovalent monodentate substituent, if present, is selected from:

hydroxy (-OH);

halo;

cyano (-CN);

carboxy (-COOH);

azido;

ester;

amino, including:

C₁₋₇alkyl-amino;

amino-C₁₋₇alkyl-amino;

C₁₋₇alkyl, including:

halo-C₁₋₇alkyl;

amino-C₁₋₇alkyl;

carboxy-C₁₋₇alkyl;

hydroxy-C₁₋₇alkyl;

C₅₋₂₀aryl-C₁₋₇alkyl;

ether, including:

C₁₋₇alkoxy;

halo-C₁₋₇alkoxy;

amino-C₁₋₇alkoxy;


carboxy-C₁₋₇alkoxy;
hydroxy-C₁₋₇alkoxy;
C₅₋₂₀aryl-C₁₋₇alkoxy;
acyl, including:
C₁₋₇alkyl-acyl;
halo-C₁₋₇alkyl-acyl;
amino-C₁₋₇alkyl-acyl;
carboxy-C₁₋₇alkyl-acyl;
hydroxy-C₁₋₇alkyl-acyl;
C₅₋₂₀aryl-C₁₋₇alkyl-acyl;
C₅₋₂₀aryl-acyl;
C₅₋₂₀aryl;
thiol (-SH); and,
thioether.

139. (new) A compound according to claim 138, wherein each monovalent monodentate substituent, if present, is selected from: hydroxy, halo, C₁₋₇alkoxy, thiol, and thioether.


140. (new) A compound according to claim 138, wherein each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H or is selected from: hydroxyl, halo, C₁₋₇alkyl, and C₁₋₇alkoxy.

141. (new) A compound according to claim 139, wherein each of R^{3N}, R^{4N}, R^{5N}, R^{6N}, and R^{7N} is independently -H or is selected from: hydroxyl, halo, C₁₋₇alkyl, and C₁₋₇alkoxy.


142. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:




143. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



144. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:




145. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



146. (new) A compound according to claim 145, wherein each monovalent monodentate substituent, if present, is selected from: halo, thiol, and thioether.

147. (new) A compound according to claim 141, selected from compounds of the following formula and pharmaceutically acceptable salts, esters, amides, solvates, and hydrates thereof:



148. (new) A compound according to claim 147, wherein each monovalent monodentate substituent, if present, is selected from: halo, thiol, and thioether.

149. (new) A compound according to claim 147, wherein one or both of R³ and R⁵ is a thiol or a thioether group.

150. (new) A compound according to claim 147, wherein each of R³ and R⁵ is a thiol or a thioether group.

151. (new) A compound according to claim 141, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

152. (new) A compound according to claim 142, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

153. (new) A compound according to claim 143, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

154. (new) A compound according to claim 144, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

155. (new) A compound according to claim 145, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

156. (new) A compound according to claim 147, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

157. (new) A compound according to claim 150, wherein R^{SO} is phenyl or naphthyl, and is optionally substituted.

158. (new) A compound according to claim 141, wherein wherein R^O is -H.

159. (new) A compound according to claim 142, wherein wherein R^O is -H.

160. (new) A compound according to claim 143, wherein wherein R^O is -H.

161. (new) A compound according to claim 145, wherein wherein R^O is -H.

162. (new) A compound according to claim 147, wherein wherein R^O is -H.

163. (new) A compound according to claim 150, wherein wherein R^O is -H.

164. (new) A compound according to claim 151, wherein wherein R^O is -H.

165. (new) A compound according to claim 152, wherein wherein R^O is -H.

166. (new) A compound according to claim 153, wherein wherein R^O is -H.



167. (new) A compound according to claim 154, wherein wherein R^O is -H.

168. (new) A compound according to claim 155, wherein wherein R^O is -H.

169. (new) A compound according to claim 156, wherein wherein R^O is -H.


170. (new) A compound according to claim 157, wherein wherein R^O is -H.

171. (new) A compound selected from compounds of the following formulae and pharmaceutically acceptable salts, esters, solvates, and hydrates thereof:



wherein:

Ar is a group of the following formula:



and wherein:



each of R^3 and R^5 , if present, is independently a thiol or thioether group;





R^O is independently -H;





R^{SO} is independently phenyl, and is optionally substituted; and





R^{5N} is independently -H, -OH, -F, -Cl, -Br, -I, -Me, -Et, -OMe, or -OEt.



172. (new) A compound selected from the following compounds and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof:












173. (new) A compound selected from the following compound and pharmaceutically acceptable salts, esters, solvates, and hydrates thereof:



174. (new) A composition comprising a compound according to claim 138 and a pharmaceutically acceptable carrier or diluent.

175. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

176. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

177. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

178. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

179. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 138.

180. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

181. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

182. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

183. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

184. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 171.

185. (new) A method of treatment of colon cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

186. (new) A method of treatment of renal cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

187. (new) A method of treatment of breast cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

188. (new) A method of treatment of CNS cancer comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.

189. (new) A method of treatment of melanoma comprising administering to a subject suffering from said cancer a therapeutically-effective amount of a compound according to claim 173.